Multidrug resistant to extensively drug resistant tuberculosis: What is next? (original) (raw)
Baltussen R, Floyd K and Dye C 2005 Cost effectiveness analysis of strategies for tuberculosis control in developing countries; Br. Med. J.331 1364 Article Google Scholar
Blumberg H M, Burman W J, Chaisson R E, Daley C L, Etkind S C, Friedman L N, Fujiwara P, Grzemska M, et al 2003 American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis; Am. J. Respir. Crit. Care Med.167 603–662 ArticlePubMed Google Scholar
Bouvet E 2007 Multidrug resistant tuberculosis: What is the risk in France?; Rev. Prat.15 1405–1408 Google Scholar
Carpenter J L, Obnibene A J, Gorby E W, Neimes R E, Koch J and Perkins W L 1983 Antituberculosis drug resistance in south Texas; Am. Rev. Respir. Dis.128 1055–1058 ArticleCASPubMed Google Scholar
Centers for Disease Control and Prevention 2006 Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide; MMWR55 301–305 Google Scholar
Chan E D and Iseman M D 2002 Current medical treatment for tuberculosis; Br. Med. J.325 1282–1286 Article Google Scholar
Datta M, Radhamani M P, Selvaraj R, Paramasivan C N, Gopalan B N, Sudeendra C R and prabhakar R, et al 1993 Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme; Tuber. Lung Dis.74 180–186 ArticleCASPubMed Google Scholar
DeRiemer K, Garcia-Garcia L and Bobadilla-del-Valle M 2005 Does DOTS work in populations with drug-resistant tuberculosis?; Lancet365 1239–1245 ArticlePubMed Google Scholar
Drobniewski F A and Balabanova Y M 2002 The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millennium; Int. J. Infect. Dis.6 S21–S31 ArticlePubMed Google Scholar
Drobniewski F, Eltringham I, Graham C, Magee J G, Smith E G and Watt B 2002 A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK; Thorax5723 810–816 ArticleCASPubMedPubMed Central Google Scholar
Editorial 2007 Stopping tuberculosis proves hard to do; Lancet369 965 Article Google Scholar
Espinal M A and Dye C 2005 Can DOTS control multidrug-resistant tuberculosis?; Lancet365 1206–1209 ArticlePubMed Google Scholar
Espinal M A, Dye C, Raviglione M, et al 1999 Rational ‘DOT plus’ for the control of MDR-TB; Int. Tuberc. Lung Dis.3 561–563 CAS Google Scholar
Espinal M A, Kim S J, Suarez P G, et al 2000 Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA283 2537–2545 ArticleCASPubMed Google Scholar
Farmer P and Kim J Y 1998 Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus”; Br. Med. J.317 671–674 ArticleCAS Google Scholar
Flament-Saillour M, Robert J, Jarlier V, et al 1999 Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study; Am. J. Respir. Crit. Care Med.160 587–593 ArticleCASPubMed Google Scholar
Floyd K, Hutubessy R, Samyshkin E, et al 2006 Health-systems efficiency in the Russian Federation: tuberculosis control. Bull.WHO84 43–51 PubMed Google Scholar
Gandhi N R, Moll A and Sturm A W 2006 Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa; Lancet368 1575–1580 ArticlePubMed Google Scholar
Giovanni Di Perri and Stefano Bonora 2004 Which agents should we use for the treatment of multidrug- resistant Mycobacterium tuberculosis?; J. Antimicrob. Chemother.54 593–602 Article Google Scholar
Goble M, Iseman M D, Madsen L A, et al 1993 Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin; N. Engl. J. Med.328 527–532 ArticleCASPubMed Google Scholar
Gupta R, Cegielski J P, Espinal M A, et al 2002 Increasing transparency for health: introducing the Green Light Committee; Trop. Med. Int. Health7 970–976 ArticlePubMed Google Scholar
Gupta R and Espinal M and Stop TB Working Group on DOTS-Plus for MDR-TB 2003 A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB); Int. J. Tuberc. Lung Dis.7 410–414 PubMed Google Scholar
Gupta R, Raviglione and Espinal M A 2001 Should tuberculosis programmes invest in second line treatments for multidrug-resistant tuberculosis (MDR-TB)?; Int. J. Tuberc. Lung Dis.5 1078–1079 CASPubMed Google Scholar
Heifets L B and Cangelosi G A 1999 Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century; Int. J. Tuberc. Lung Dis.3 564–581 CASPubMed Google Scholar
Holtz T H, Riekstina V, Zarovska E, et al 2005 XDR-TB: extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000–2002; Int. J. Tuberc. Lung Dis. (Suppl. 1)9 S258 Google Scholar
Hopewell P C, Pai M, Maher D, et al 2006 International standards for Tuberculosis care; Lancet Infect. Dis.6 710–725 ArticlePubMed Google Scholar
Huong N T, Lan N T, Cobelens F G, et al 2006 Antituberculosis drug resistance in the south of Vietnam: prevalence and trends; J. Infect. Dis.194 1226–1232 ArticlePubMed Google Scholar
Jacqui W 2006 Southern Africa is moving swiftly to combat the threat of XDR-TB; Bull. WHO84 924–925 Google Scholar
Jacaban R F 1994 Multiple drug Resstant Tuberculosis; Clin. Infect. Dis.19 1–10 Article Google Scholar
Jeon C Y, Hwang S H, Min J H, et al 2008 Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital; Clin. Infect. Dis.46 42–49 ArticlePubMed Google Scholar
Johnson J, Kagal A and Bharadwaj R 2003 Factors associated with drug resistance in pulmonary tuberculosis; Indian J. Chest Dis. Allied Sci.45 105–109 PubMed Google Scholar
Kam K M and Yip C W 2004 Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995–2002, after the implementation of DOTS-plus; Int. J. Tuberc. Lung Dis.8 760–766 CASPubMed Google Scholar
Kato-Maeda M, Bifani P J, Krieswirth B N, et al 2001 The nature and consequence of genetic variability in Mycobacterium tuberculosis; J. Clin. Invest.107 533–537 ArticleCASPubMedPubMed Central Google Scholar
Kato-Maeda, M, Rhee J T, Gingeras T R, et al 2001 Comparing genomes within the species Mycobacterium tuberculosis; Genome Res.11 547–555 ArticleCASPubMedPubMed Central Google Scholar
Kim H R, Hwang S S, Kim H J, et al 2007 Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis; Clin. Infect. Dis.45 1290–1295 ArticlePubMed Google Scholar
Leimane V, Rickstina V, Holtz T H, et al 2005 Clinical outcome of individualized treatment of multidrug resistant tuberculosis in Latvia: A retrospective cohort study; Lancet365 318–326 ArticlePubMed Google Scholar
Masjedi M R, Farnia P, Sorooch S, et al 2006 Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran; Clin. Infect. Dis.43 841–847 ArticleCASPubMed Google Scholar
Matteelli A, Migliori G B, Cirillo D, et al 2007 Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control; Exp. Rev. Anti Infect. Ther.5 857–871 ArticleCAS Google Scholar
Migliori G B, Loddenkemper R, Blasi F, et al 2007a 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?; Eur. Respir. J.29 423–427 ArticleCASPubMed Google Scholar
Migliori G, Ortman J, Giardi E, et al 2007b Extensively drug-resistant tuberculosis, Italy and Germany; Emerg. Infect. Dis.13 1–4 Article Google Scholar
Mitnick C, Bayona J, Palacios E, et al 2003 Community-based therapy for multidrug- resistant tuberculosis in Lima, Peru; N. Engl. J. Med.348 119–128 ArticlePubMed Google Scholar
Mlambo C K, Warren R M, Poswa X, et al 2008 Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa; Int. J. Tuberc. Lung Dis.12 99–104 CASPubMed Google Scholar
Mukherjee J S, Rich M L, Socci AR, et al 2004 Programmes and principles in treatment of multidrug- resistant tuberculosis; Lancet363 474–481 ArticlePubMed Google Scholar
Narain J P and Lo Y R 2004 Epidemiology of HIV-TB in Asia; Indian J. Med. Res.120 277–289 PubMed Google Scholar
Nathanson E, Lambregts-van Wezenbeek C, Rich M L, et al 2006 Multidrug-resistant tuberculosis management in resource-limited settings; Emerg. Infect. Dis.12 1389–1397 ArticlePubMedPubMed Central Google Scholar
Ormerod L P 2005 Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment; Br. Med. Bull.73–74 17–24 ArticlePubMed Google Scholar
Park M H, Song E Y, Park H J, et al 2002 HLA-DRB1 and DQB1 gene polymorphism is associated with multidrug-resistant tuberculosis in Korean patients; Hum. Immunol.63 S33 Article Google Scholar
Park M M, Davis A L, Schluger N W, et al 1996 Outcome of MDRTB patients, 1983–1993. Prolonged survival with appropriate therapy; Am. J. Respir. Crit. Care Med.153 317–324 ArticleCASPubMed Google Scholar
Pillay M and Sturm A W 2007 Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa; Clin. Infect. Dis.45 1409–1414 ArticleCASPubMed Google Scholar
Prasad R 2005 MDR TB: Current Status; Indian J. Tuberc.52 121–131 Google Scholar
Prasad R and Garg R 2007 XDR-TB: An emerging threat; Chest India8 3–4 Google Scholar
Prasad R, Nautiyal R G, Mukherji P K, et al 2002 Treatment of new pulmonary tuberculosis patients: what do allopathic doctors do in India?; Int. J. Tuberc. Lung Dis.6 895–902 CASPubMed Google Scholar
Rajbhandary S S, Marks S M and Bock N N 2004 Cost of patients hospitalized for multidrug resistant tuberculosis; Int. J. Tuberc. Lung Dis.8 1012–1016 CASPubMedPubMed Central Google Scholar
Rai S P and Panda B N 2004 Outcome in Multidrug Resistant Tuberculosis patients with ambulatory treatment; Indian J. Tuberc.51 33–36 Google Scholar
Ramaswamy S and Musser J M 1998 Molecular genetic basis of anti-microbial agent resistance in Mycobacterium tuberculosis: 1998 update; Tuber. Lung Dis.79 3–29 ArticleCASPubMed Google Scholar
Shah S N, Wright A and Drobniewski F 2005 Extreme drug resistance in tuberculosis (“XDR-TB”): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs; Int. J. Tuberc. Lung Dis. (Suppl 1)9 S77 Google Scholar
Shah S N, Wright, A, Bai H G, et al 2007 Worldwide emergence of extensively drug-resistant tuberculosis; Emer. Infect. Dis.13 380–387 ArticleCAS Google Scholar
Sharma S K and Mohan A 2006 Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control; Chest130 261–272 ArticleCASPubMed Google Scholar
Sharma S K and Mohan A 2004 Multidrug-resistant tuberculosis; Indian J. Med. Res.120 354–376 CASPubMed Google Scholar
Sharma S K and Mohan A 2003 Scientific basis of directly observed treatment, short course (DOTS); J. Indian Med. Assoc.101 157–158,166 CASPubMed Google Scholar
Sharma S K, Turaga K K, Balamurugan A, et al 2003 Clinical and genetic risk factors for the development of multidrug-resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study; Infect. Genet. Evol.3 183–188 ArticlePubMed Google Scholar
Singh S, Sankar M M and Gopinath K 2008 High rate of extensively drug-resistant tuberculosis in Indian AIDS patients; AIDS21 2345–2347 Article Google Scholar
Stop T B Partnership 2006 The STOP TB strategy: building on and enhancing DOTS to meet the TB-related millennium development goals (Geneva: World Health Organization) Google Scholar
Tahaoglu K, Torun T, Sevim T, et al 2001 The treatment of multidrug-resistant tuberculosis in Turkey; N. Engl. J. Med.345 170–174 ArticleCASPubMed Google Scholar
Thomas A, Ramachandran R, Rehaman F, et al 2007 Management of multidrug resistance tuberculosis in the field: Tuberculosis Research Centre experience; Indian J. Tuberc.54 117–124 PubMed Google Scholar
Tomioka H 2002 Prospects for development of new antituberculous drug; Kekkaku77 573–584 CASPubMed Google Scholar
Tomioka H and Namba K 2006 Development of antituberculous drugs: current status and future prospects; Kekkaku81 753–774 PubMed Google Scholar
Uplekar M 2003 Involving private health care providers in delivery of TB care: Global Strategy; Tuberculosis83 156–164 ArticlePubMed Google Scholar
Uplekar M W and Shepard D S 1991 Treatment of tuberculosis by private general practiceners in India; Tubercle72 284–290 ArticleCASPubMed Google Scholar
Van Deum A, Salim M A, Das A P, Bastian I and Potales F 2004 Results of a standardized regimen for multidrug resistant tuberculosis in Bangladesh; Int. J. Tuberc. Lung Dis.8 560–567 Google Scholar
Weyer K and Kleeberg H H 1992 Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement; Tuber. Lung Dis.73 106–112 ArticleCASPubMed Google Scholar
World Health Organization Report 2008 Global Tuberculosis Control pp 109–112
World Health Organization 2006 Extensively drug-resistant tuberculosis (XDR.TB): recommendations for prevention and control; Weekly Epidemiol. Rec.81 430–432 Google Scholar